Christine M Khosropour1, Lisa E Manhart2, Catherine W Gillespie3, M Sylvan Lowens4, Matthew R Golden5, Nicole L Jensen6, George E Kenny6, Patricia A Totten6. 1. Department of Epidemiology, University of Washington, Seattle, WA, USA. 2. Department of Epidemiology, University of Washington, Seattle, WA, USA Department of Global Health, University of Washington, Seattle, WA, USA. 3. Department of Epidemiology, University of Washington, Seattle, WA, USA Children's National Health System, Washington, DC, USA. 4. Public Health - Seattle and King County HIV/STD Program, Seattle, WA, USA. 5. Department of Epidemiology, University of Washington, Seattle, WA, USA Public Health - Seattle and King County HIV/STD Program, Seattle, WA, USA Department of Medicine, University of Washington, Seattle, WA, USA. 6. Department of Medicine, University of Washington, Seattle, WA, USA.
Abstract
OBJECTIVE: Ureaplasma urealyticum biovar 2 (UU-2), but not Ureaplasma parvum (UP), has been associated with non-gonococcal urethritis (NGU), but little is known about species-specific responses to standard therapies. We examined species-specific treatment outcomes and followed men with treatment failure for 9 weeks. METHODS:From May 2007 to July 2011, men aged ≥16 attending a sexually transmitted disease (STD) clinic in Seattle, Washington, with NGU (urethral discharge or urethral symptoms plus ≥5 polymorphonuclear leucocytes /high-powered field) enrolled in a double-blind, randomised trial. Participants received active azithromycin (1 g) + placebo doxycycline or active doxycycline (100 mg twice a day ×7 days) + placebo azithromycin. Ureaplasma were detected in culture followed by species-specific PCR. Outcomes were assessed at 3, 6 and 9 weeks. At 3 weeks, men with persistent Ureaplasma detection received 'reverse therapy' (e.g., active doxycycline if they first received active azithromycin). At 6 weeks, persistently positive men received moxifloxacin (400 mg×7 days). RESULTS:Of 490 men, 107 (22%) and 60 (12%) were infected with UU-2 and UP, respectively, and returned at 3 weeks. Persistent detection was similar for UU-2-infected men initially treated with azithromycin or doxycycline (25% vs. 31%; p=0.53), but differed somewhat for men with UP (45% vs. 24%; p=0.11). At 6 weeks, 57% of UU-2-infected and 63% of UP-infected men who received both drugs had persistent detection. Failure after moxifloxacin occurred in 30% and 36%, respectively. Persistent detection of UU-2 or UP was not associated with signs/symptoms of NGU. CONCLUSIONS:Persistent detection after treatment with doxycycline, azithromycin and moxifloxacin was common for UU and UP, but not associated with persistent urethritis. TRIAL REGISTRATION NUMBER: NCT00358462. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
RCT Entities:
OBJECTIVE:Ureaplasma urealyticum biovar 2 (UU-2), but not Ureaplasma parvum (UP), has been associated with non-gonococcal urethritis (NGU), but little is known about species-specific responses to standard therapies. We examined species-specific treatment outcomes and followed men with treatment failure for 9 weeks. METHODS: From May 2007 to July 2011, men aged ≥16 attending a sexually transmitted disease (STD) clinic in Seattle, Washington, with NGU (urethral discharge or urethral symptoms plus ≥5 polymorphonuclear leucocytes /high-powered field) enrolled in a double-blind, randomised trial. Participants received active azithromycin (1 g) + placebo doxycycline or active doxycycline (100 mg twice a day ×7 days) + placebo azithromycin. Ureaplasma were detected in culture followed by species-specific PCR. Outcomes were assessed at 3, 6 and 9 weeks. At 3 weeks, men with persistent Ureaplasma detection received 'reverse therapy' (e.g., active doxycycline if they first received active azithromycin). At 6 weeks, persistently positive men received moxifloxacin (400 mg×7 days). RESULTS: Of 490 men, 107 (22%) and 60 (12%) were infected with UU-2 and UP, respectively, and returned at 3 weeks. Persistent detection was similar for UU-2-infectedmen initially treated with azithromycin or doxycycline (25% vs. 31%; p=0.53), but differed somewhat for men with UP (45% vs. 24%; p=0.11). At 6 weeks, 57% of UU-2-infected and 63% of UP-infected men who received both drugs had persistent detection. Failure after moxifloxacin occurred in 30% and 36%, respectively. Persistent detection of UU-2 or UP was not associated with signs/symptoms of NGU. CONCLUSIONS: Persistent detection after treatment with doxycycline, azithromycin and moxifloxacin was common for UU and UP, but not associated with persistent urethritis. TRIAL REGISTRATION NUMBER: NCT00358462. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Janet A Robertson; Gerald W Stemke; John W Davis; Ryĵ Harasawa; David Thirkell; Fanrong Kong; Maurice C Shepard; Denys K Ford Journal: Int J Syst Evol Microbiol Date: 2002-03 Impact factor: 2.747
Authors: Lisa E Manhart; Catherine W Gillespie; M Sylvan Lowens; Christine M Khosropour; Danny V Colombara; Matthew R Golden; Navneet R Hakhu; Katherine K Thomas; James P Hughes; Nicole L Jensen; Patricia A Totten Journal: Clin Infect Dis Date: 2012-12-07 Impact factor: 9.079
Authors: W E Stamm; C B Hicks; D H Martin; P Leone; E W Hook; R H Cooper; M S Cohen; B E Batteiger; K Workowski; W M McCormack Journal: JAMA Date: 1995-08-16 Impact factor: 56.272
Authors: Susan M Dutro; Jennifer K Hebb; Cresley A Garin; James P Hughes; George E Kenny; Patricia A Totten Journal: Sex Transm Dis Date: 2003-10 Impact factor: 2.830